🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Pediatric Solid Tumors

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors NCT04222413Phase 12 sites📍 Fairway📍 Bethesda National Cancer Institute (NCI) · Tests: Metarrestin Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents NCT05151718n/a1 site📍 Toulouse Institut Claudius Regaud A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) NCT06941272Phase 1, Phase 264 sites📍 Los Angeles📍 Aurora📍 New Haven Merck Sharp & Dohme LLC · Tests: Patritumab Deruxtecan Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors NCT05372640Phase 17 sites📍 Los Angeles📍 Los Angeles📍 Los Angeles National Cancer Institute (NCI) · Tests: Abemaciclib, BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer NCT06636435Phase 15 sites📍 Kashiwa📍 Yokohama📍 Niigata Chiome Bioscience Inc. · Tests: CBA-1205 Part 1, CBA-1205 Part 2, CBA-1205 Part 3, CBA-1205 Part 4, CBA-1205 Part 5 Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors NCT03934372Phase 1, Phase 223 sites📍 Ghent📍 Paris📍 Paris Incyte Biosciences International Sàrl · Tests: Ponatinib Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors NCT06047977Phase 11 site📍 St. Petersburg H. Lee Moffitt Cancer Center and Research Institute · Tests: Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2 Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors NCT06926751Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Telpegfilgrastim Injection, filgrastim A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients NCT05711667Phase 333 sites📍 Birmingham📍 Oakland📍 San Francisco Children's Oncology Group · Tests: Biospecimen Collection, Letermovir Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies NCT01109394n/a5 sites📍 Washington D.C.📍 Orange📍 Bethesda National Cancer Institute (NCI) Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) NCT06395103Phase 1, Phase 271 sites📍 Los Angeles📍 Aurora📍 New Haven Merck Sharp & Dohme LLC · Tests: Zilovertamab vedotin Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells NCT07148050Phase 11 site📍 Seattle Seattle Children's Hospital · Tests: SC-CAR.GPC3xIL15.21 CAR T cells Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Becotatug Vedotin Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy NCT06579469n/a6 sites📍 Aurora📍 Philadelphia📍 Memphis St. Jude Children's Research Hospital B7-H3.CD28Z.CART in Solid Tumors NCT07358260Phase 11 site📍 Boston Robbie Majzner · Tests: B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) NCT04897321Phase 11 site📍 Memphis St. Jude Children's Research Hospital · Tests: Fludarabine, Cyclophosphamide, MESNA, B7-H3 CAR T cells Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling NCT05857969Phase 11 site📍 Miami Florida International University · Tests: Functional Precision Medicine Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer NCT07756034n/a1 site📍 Chicago Tempus AI Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors NCT05645523EARLY Phase 13 sites📍 Chicago📍 Pittsburgh📍 Memphis St. Jude Children's Research Hospital · Tests: Indocyanine Green A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) NCT07630974Phase 1, Phase 234 sites📍 Los Angeles📍 Aurora📍 St. Petersburg Merck Sharp & Dohme LLC · Tests: Ifinatamab Deruxtecan Liquid Biopsies in Pediatric Solid Tumors NCT05068583n/a1 site📍 Los Angeles Children's Hospital Los Angeles · Tests: Blood Draw Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence NCT02446431EARLY Phase 12 sites📍 Long Beach📍 Orange Miller Children's & Women's Hospital Long Beach · Tests: Bevacizumab, Cyclophosphamide, Valproic Acid, Temsirolimus Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors NCT06441331Phase 17 sites📍 San Francisco📍 Cincinnati📍 Philadelphia ITM Solucin GmbH · Tests: Lutetium Lu 177-Edotreotide, Amino Acid Solution A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment NCT04928677Phase 15 sites📍 Los Angeles📍 Atlanta📍 Boston Memorial Sloan Kettering Cancer Center · Tests: Codrituzumab Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology NCT05306509NA1 site📍 Shanghai Children's Hospital of Fudan University · Tests: NiCE, Routine PPC Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma NCT07502287Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-DTNB-NK, Fludarabine, Cyclophosphamide Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) NCT05521984Phase 11 site📍 St Louis Washington University School of Medicine · Tests: Dapagliflozin, Carmustine, Topotecan, Cyclophosphamide Development and Application of Intervention Program to Improve Mental Health and Quality of Life of Solid Tumor Survivors and Caregivers NCT06969742NA3 sites📍 Goyang-si📍 Seoul📍 Seoul National Cancer Center, Korea · Tests: Psycho-education and Psychological intervention_After cancer treatment, Psycho-education and Psychological intervention… MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 NCT05691608NA29 sites📍 Amiens📍 Paris📍 Saint-Etienne Gustave Roussy, Cancer Campus, Grand Paris · Tests: Solid tumor and CT DNA Molecular Analysis Of Solid Tumors NCT01050296n/a1 site📍 Memphis St. Jude Children's Research Hospital
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy